Martin Huber

Martin Huber

Director/Board Member at SYNDAX PHARMACEUTICALS, INC.

Net worth: 1 M $ as of 31/05/2026

66 year
Health Technology
Consumer Services

Profile

Martin H.
Huber
is currently an Independent Director at Syndax Pharmaceuticals, Inc. since 2021 and an Independent Director at Actuate Therapeutics, Inc. starting in 2026.
Former positions include President, Chief Executive Officer & Director at Mersana Therapeutics, Inc. from 2023 to 2026; President, Head-Research & Development at Xilio Therapeutics, Inc. from 2022 to 2023; Senior Vice President-Clinical at GSK Plc from 2019 to 2020; Chief Medical Officer & Senior Vice President at Tesaro, Inc. from 2015 to 2019; Vice President-Oncology Clinical Research at Merck Research Laboratories Massachusetts LLC from 2012 to 2015; Vice President-Global Pharmacovigilance at Schering-Plough Corp.; Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
Education includes undergraduate studies at Texas Lutheran University and a doctorate from Baylor College of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/03/2026 74,000 ( 0.08% ) 1 M $ 31/05/2026

Martin Huber active positions

CompaniesPositionStart
SYNDAX PHARMACEUTICALS, INC. Director/Board Member 15/09/2021
ACTUATE THERAPEUTICS, INC. Director/Board Member 01/05/2026

Former positions of Martin Huber

CompaniesPositionEnd
MERSANA THERAPEUTICS Chief Executive Officer 06/01/2026
XILIO THERAPEUTICS, INC. President 08/09/2023
GSK PLC Chief Tech/Sci/R&D Officer 01/04/2020
TESARO INC Chief Tech/Sci/R&D Officer 22/01/2019
Corporate Officer/Principal 01/01/2015
See the detail of Martin Huber's experience

Training of Martin Huber

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

39

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!